A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A phase 2 trial of Denileukin diftitox in Ovarian cancer, run by The University of Texas Health Science Center at San Antonio, completed.
Overview
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer is a phase 2 interventional study registered as NCT00880360 by The University of Texas Health Science Center at San Antonio, with 19 participants recorded, started 2007-02 and reaching its primary completion in 2010-04. Interventions recorded: Ontak. Conditions recorded: Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma.
Linked to the drug Denileukin diftitox because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPhase II Trial of Ontak With Metastatic Melanoma
Shares Denileukin diftitox and the tag pipeline.
- TrialStudy of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Shares Denileukin diftitox and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.